Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Jun 19. pii: nyz186. doi: 10.1093/neuros/nyz186. [Epub ahead of print] No abstract available.

PMID:
31215634
2.

Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis.

Jairam V, Kann BH, Park HS, Miccio JA, Beckta JM, Yu JB, Prabhu RS, Gao SJ, Mehta MP, Curran WJ, Bindra RS, Contessa JN, Patel KR.

Anticancer Res. 2019 Jun;39(6):2911-2918. doi: 10.21873/anticanres.13420.

PMID:
31177129
3.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
4.

The Complexity of Managing Large Brain Metastasis.

Kotecha R, Mehta MP.

Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):483-484. doi: 10.1016/j.ijrobp.2018.02.160. No abstract available.

PMID:
31162052
5.

Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Kotecha R, Mehta MP, Chang EL, Brown PD, Suh JH, Lo SS, Das S, Samawi HH, Keith J, Perry J, Sahgal A.

Neuro Oncol. 2019 Jun 10;21(6):707-718. doi: 10.1093/neuonc/noz014.

PMID:
30977511
6.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
7.

NRG brain tumor specialists consensus guidelines for glioblastoma contouring.

Kruser TJ, Bosch WR, Badiyan SN, Bovi JA, Ghia AJ, Kim MM, Solanki AA, Sachdev S, Tsien C, Wang TJC, Mehta MP, McMullen KP.

J Neurooncol. 2019 May;143(1):157-166. doi: 10.1007/s11060-019-03152-9. Epub 2019 Mar 19.

PMID:
30888558
8.

Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?

Sperduto PW, Fang P, Li J, Breen W, Brown PD, Cagney D, Aizer A, Yu J, Chiang V, Jain S, Gaspar LE, Myrehaug S, Sahgal A, Braunstein S, Sneed P, Cameron B, Attia A, Molitoris J, Wu CC, Wang TJC, Lockney N, Beal K, Parkhurst J, Buatti JM, Shanley R, Lou E, Tandberg DD, Kirkpatrick JP, Shi D, Shih HA, Chuong M, Saito H, Aoyama H, Masucci L, Roberge D, Mehta MP.

Transl Res. 2019 Jun;208:63-72. doi: 10.1016/j.trsl.2019.02.011. Epub 2019 Feb 27.

PMID:
30885538
9.

Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous.

Nieder C, Guckenberger M, Gaspar LE, Rusthoven CG, De Ruysscher D, Sahgal A, Nguyen T, Grosu AL, Mehta MP.

Radiat Oncol. 2019 Feb 15;14(1):33. doi: 10.1186/s13014-019-1237-9.

10.

Hip Arthroscopy for Femoroacetabular Impingement.

Sonnenfeld JJ, Trofa DP, Mehta MP, Steinl G, Lynch TS.

JBJS Essent Surg Tech. 2018 Aug 22;8(3):e23. doi: 10.2106/JBJS.ST.18.00043. eCollection 2018 Sep 28.

11.

What is the evidence for the clinical value of SBRT in cancer of the cervix?

Yanez L, Ciudad AM, Mehta MP, Marsiglia H.

Rep Pract Oncol Radiother. 2018 Nov-Dec;23(6):574-579. doi: 10.1016/j.rpor.2018.08.005. Epub 2018 Oct 9. Review.

PMID:
30534021
12.

Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):878-886. doi: 10.1016/j.ijrobp.2018.11.008. Epub 2018 Nov 27.

PMID:
30496882
13.

Erratum. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Rogers L, Zhang P, Vogelbaum MA, Mehta MP.

J Neurosurg. 2018 Dec 1;129(6):1650. doi: 10.3171/2018.8.JNS161170a. No abstract available.

PMID:
30485244
14.

Recent advances in managing brain metastasis.

Kotecha R, Gondi V, Ahluwalia MS, Brastianos PK, Mehta MP.

F1000Res. 2018 Nov 9;7. pii: F1000 Faculty Rev-1772. doi: 10.12688/f1000research.15903.1. eCollection 2018. Review.

15.

Low-Grade Glioma Radiotherapy Treatment and Trials.

Wang TJC, Mehta MP.

Neurosurg Clin N Am. 2019 Jan;30(1):111-118. doi: 10.1016/j.nec.2018.08.008. Epub 2018 Nov 1. Review.

PMID:
30470398
16.

Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.

Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, Beal K, Rana NG, Attia A, Tseng CL, Sahgal A, Shanley R, Sperduto WA, Lou E, Zahra A, Buatti JM, Yu JB, Chiang V, Molitoris JK, Masucci L, Roberge D, Shi DD, Shih HA, Olson A, Kirkpatrick JP, Braunstein S, Sneed P, Mehta MP.

Neuro Oncol. 2018 Nov 12;20(12):1652-1660. doi: 10.1093/neuonc/noy099.

PMID:
30418657
17.

Postoperative Management of Resected Brain Metastases: When Can Radiotherapy Be Deferred?

Mehta MP, Kotecha R.

J Clin Oncol. 2018 Oct 8:JCO2018793232. doi: 10.1200/JCO.2018.79.3232. [Epub ahead of print]

PMID:
30296192
18.

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Mansouri A, Hachem LD, Mansouri S, Nassiri F, Laperriere NJ, Xia D, Lindeman NI, Wen PY, Chakravarti A, Mehta MP, Hegi ME, Stupp R, Aldape KD, Zadeh G.

Neuro Oncol. 2019 Feb 14;21(2):167-178. doi: 10.1093/neuonc/noy132.

PMID:
30189035
19.

Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study.

Rice SR, Bentzen SM, Hanna A, Choi E, Boggs DH, Kwok Y, Hyder J, Feigenberg SJ, Regine WF, Woodworth GF, Eisenberg HM, Yu C, Biggins TF, Barnholtz-Sloan JS, Sperduto PW, Weltman E, Mehta MP.

J Neurooncol. 2018 Nov;140(2):341-349. doi: 10.1007/s11060-018-2958-6. Epub 2018 Aug 21.

PMID:
30132164
20.

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation.

Kruser TJ, Gondi V, Sperduto PW, Brown PD, Mehta MP.

Lancet Oncol. 2018 Aug;19(8):e366. doi: 10.1016/S1470-2045(18)30439-X. No abstract available.

PMID:
30102216
21.

Consolidative Whole-Brain Radiation Therapy Versus Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Large Dose of Perspective and Perhaps a Lower Dose of Radiation Are in Order.

Bovi JA, Schultz CJ, Mehta MP, Corn BW.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):59-60. doi: 10.1016/j.ijrobp.2018.04.040. Epub 2018 Apr 22. No abstract available.

PMID:
30102204
22.

Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.

Sperduto PW, Deegan BJ, Li J, Jethwa KR, Brown PD, Lockney N, Beal K, Rana NG, Attia A, Tseng CL, Sahgal A, Shanley R, Sperduto WA, Lou E, Zahra A, Buatti JM, Yu JB, Chiang V, Molitoris JK, Masucci L, Roberge D, Shi DD, Shih HA, Olson A, Kirkpatrick JP, Braunstein S, Sneed P, Mehta MP.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):845-853. doi: 10.1016/j.ijrobp.2018.04.006. Epub 2018 Apr 12.

PMID:
29976497
23.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.

JAMA Oncol. 2018 Oct 1;4(10):1405-1409. doi: 10.1001/jamaoncol.2018.1977.

24.

Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review.

Prabhu RS, Patel KR, Press RH, Soltys SG, Brown PD, Mehta MP, Asher AL, Burri SH.

Neurosurgery. 2019 Jan 1;84(1):19-29. doi: 10.1093/neuros/nyy146.

PMID:
29771381
25.

Determining glenoid component version after total shoulder arthroplasty.

Mehta MP, Vogel LA, Shiu BB, Dennis ER, Petkovic D, Levine WN, Jobin CM.

J Shoulder Elbow Surg. 2018 Sep;27(9):1588-1595. doi: 10.1016/j.jse.2018.03.003. Epub 2018 May 11.

PMID:
29759906
26.

Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms.

Nieder C, Mehta MP, Geinitz H, Grosu AL.

Crit Rev Oncol Hematol. 2018 Jun;126:13-18. doi: 10.1016/j.critrevonc.2018.03.018. Epub 2018 Mar 29. Review.

PMID:
29759555
27.

Assessing the Readability of Online Information About Hip Arthroscopy.

Mehta MP, Swindell HW, Westermann RW, Rosneck JT, Lynch TS.

Arthroscopy. 2018 Jul;34(7):2142-2149. doi: 10.1016/j.arthro.2018.02.039. Epub 2018 Apr 7.

PMID:
29631940
28.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.

Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B.

Neurosurgery. 2019 Jan 1;84(1):66-76. doi: 10.1093/neuros/nyy003.

PMID:
29618054
29.

Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells.

Hsu SPC, Kuo JS, Chiang HC, Wang HE, Wang YS, Huang CC, Huang YC, Chi MS, Mehta MP, Chi KH.

Oncotarget. 2018 Jan 3;9(6):6883-6896. doi: 10.18632/oncotarget.23855. eCollection 2018 Jan 23.

30.

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.

Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW.

Neuro Oncol. 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017.

31.

Role of Radiosensitizers in Radiation Treatment of Gliomas.

Cohen RJ, Mehta MP.

Prog Neurol Surg. 2018;31:102-115. doi: 10.1159/000467142. Epub 2018 Jan 25.

PMID:
29393180
32.

Repeat reirradiation of the spinal cord: multi-national expert treatment recommendations.

Nieder C, Gaspar LE, Ruysscher D, Guckenberger M, Mehta MP, Rusthoven CG, Sahgal A, Gkika E.

Strahlenther Onkol. 2018 May;194(5):365-374. doi: 10.1007/s00066-018-1266-6. Epub 2018 Jan 23.

PMID:
29362835
33.

Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group.

Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review.

PMID:
29304360
34.

Reply to M.C. Chamberlain.

Glass J, Werner-Wasik M, Mehta MP.

J Clin Oncol. 2016 Nov 20;34(33):4057. doi: 10.1200/JCO.2016.69.6047. Epub 2016 Oct 31. No abstract available.

PMID:
29236594
35.

Control versus cognition: the changing paradigm of adjuvant therapy for resected brain metastasis.

Gondi V, Mehta MP.

Neuro Oncol. 2018 Jan 10;20(1):2-3. doi: 10.1093/neuonc/nox180. No abstract available.

36.

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, Fiveash JB, Mohile NA, Ahluwalia MS, Wendland MM, Stella PJ, Kee AY, Mehta MP.

Neuro Oncol. 2018 Apr 9;20(5):666-673. doi: 10.1093/neuonc/nox209.

37.

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.

Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

38.

Brain Metastases in Lung Cancer With Targetable Mutations-Reply.

Sperduto PW, Mehta MP.

JAMA Oncol. 2018 Mar 1;4(3):422-423. doi: 10.1001/jamaoncol.2017.3375. No abstract available.

PMID:
29049682
39.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

40.

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP.

J Neurosurg. 2018 Jul;129(1):35-47. doi: 10.3171/2016.11.JNS161170. Epub 2017 Oct 6. Erratum in: J Neurosurg. 2018 Dec 1;129(6):1650.

41.

State of the art: the evolving role of RT in combined modality therapy for GBM.

Bindra RS, Galanis E, Mehta MP.

J Neurooncol. 2017 Sep;134(3):477-478. doi: 10.1007/s11060-017-2596-4. No abstract available.

42.

The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.

Burri SH, Gondi V, Brown PD, Mehta MP.

Am J Clin Oncol. 2018 Feb;41(2):191-196. doi: 10.1097/COC.0000000000000395. Review.

43.

Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.

Molitoris JK, Rao YJ, Patel RA, Kane LT, Badiyan SN, Gittleman H, Barnholtz-Sloan JS, Bentzen SM, Kruser TJ, Huang J, Mehta MP.

J Neurooncol. 2017 Sep;134(2):331-338. doi: 10.1007/s11060-017-2529-2. Epub 2017 Jun 22.

PMID:
28643151
44.

A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.

Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, James SE, Evans JD, Spears GM, Komaki R, Haddock MG, Mehta MP, Hallemeier CL, Merrell KW.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):820-828. doi: 10.1016/j.ijrobp.2017.02.021. Epub 2017 Feb 20.

PMID:
28476435
45.

Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.

Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL.

Radiother Oncol. 2017 Jun;123(3):376-381. doi: 10.1016/j.radonc.2017.04.013. Epub 2017 Apr 25.

PMID:
28455153
46.

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.

Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208.

47.

Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.

Nieder C, De Ruysscher D, Gaspar LE, Guckenberger M, Mehta MP, Cheung P, Sahgal A.

Strahlenther Onkol. 2017 Jul;193(7):515-524. doi: 10.1007/s00066-017-1130-0. Epub 2017 Apr 19.

PMID:
28424839
48.

Genetic landscape of extreme responders with anaplastic oligodendroglioma.

Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, Kinzler K, Jenkins RB, Bettegowda C.

Oncotarget. 2017 May 30;8(22):35523-35531. doi: 10.18632/oncotarget.16773.

49.

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.

Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025.

50.

The role of radiation in treating glioblastoma: here to stay.

Corso CD, Bindra RS, Mehta MP.

J Neurooncol. 2017 Sep;134(3):479-485. doi: 10.1007/s11060-016-2348-x. Epub 2017 Mar 7. Review.

PMID:
28271281

Supplemental Content

Loading ...
Support Center